Literature DB >> 11971651

Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine.

S Gupta1, M M Thapar, S T Mariga, W H Wernsdorfer, A Björkman.   

Abstract

In the scenario of drug-resistant Plasmodium falciparum malaria combination therapy represents an effective approach. Artemisinin and its derivatives are of special interest because they represent the most effective group of compounds against multidrug-resistant malaria with a rapid onset of action and a short half-life. Interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine were therefore investigated against three strains of P. falciparum using a 48-h in vitro culture assay. Two of the strains were chloroquine sensitive and one was partially chloroquine resistant. Observed effective concentrations (O) of the combined compounds at different concentration ratios were calculated for different degrees of inhibition (EC50, EC90, EC99) and compared to expected calculated effective concentrations (E) using a probit method. Synergism with mean O/E EC90 values of 0.25 and 0.8 were found with the combination of artemisinin and the two Mannich bases, amodiaquine and pyronaridine, respectively, whereas chloroquine showed addition with a mean value of 1.2. Although both amodiaquine and chloroquine are 4-aminoquinolines, their interaction with artemisinin appears to be different. The combination of artemisinin with amodiaquine represents an important option for the treatment of falciparum malaria. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971651     DOI: 10.1006/expr.2001.4659

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  7 in total

1.  In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs.

Authors:  Timothy M E Davis; Juliana Hamzah; Kenneth F Ilett; Harin A Karunajeewa; John C Reeder; Kevin T Batty; Sara Hackett; P Hugh R Barrett
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.

Authors:  Brioni R Moore; Madhu Page-Sharp; Jillian R Stoney; Kenneth F Ilett; Jeffrey D Jago; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

3.  Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro.

Authors:  S T Mariga; J P Gil; C Sisowath; W H Wernsdorfer; A Björkman
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial.

Authors:  Frank O Odhiambo; Mary J Hamel; John Williamson; Kim Lindblade; Feiko O ter Kuile; Elizabeth Peterson; Peter Otieno; Simon Kariuki; John Vulule; Laurence Slutsker; Robert D Newman
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

5.  Review of pyronaridine anti-malarial properties and product characteristics.

Authors:  Simon L Croft; Stephan Duparc; Sarah J Arbe-Barnes; J Carl Craft; Chang-Sik Shin; Lawrence Fleckenstein; Isabelle Borghini-Fuhrer; Han-Jong Rim
Journal:  Malar J       Date:  2012-08-09       Impact factor: 2.979

6.  1-Bromo-2-(10β-dihydro-artemisin-oxy)ethane.

Authors:  Marli C Lombard; Manuel A Fernandes; Jaco C Breytenbach; David D N'da
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-07-31

Review 7.  CYP2C8 and antimalaria drug efficacy.

Authors:  J P Gil; E Gil Berglund
Journal:  Pharmacogenomics       Date:  2007-02       Impact factor: 2.533

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.